Armata Historical Balance Sheet

ARMP Stock

USD 2.29 0.04 1.78%

Trend analysis of Armata Pharmaceuticals balance sheet accounts such as Short Long Term Debt Total of 126.4 M, Total Current Liabilities of 17.3 M or Property Plant And Equipment Net of 60.1 M provides information on Armata Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Armata Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Armata Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Armata Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Armata Pharmaceuticals is a good buy for the upcoming year.

Armata Pharmaceuticals Inventory

(2.56 Million)

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Armata Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Armata Stock, please use our How to Invest in Armata Pharmaceuticals guide.

About Armata Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Armata Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Armata Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Armata Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Armata currently owns. An asset can also be divided into two categories, current and non-current.

Armata Pharmaceuticals Balance Sheet Chart

At this time, Armata Pharmaceuticals' Non Current Liabilities Total is relatively stable compared to the past year. As of 11/26/2024, Other Current Assets is likely to grow to about 2.3 M, while Retained Earnings are likely to drop (324.3 M).

Total Assets Short Long Term Debt Total Total Current Liabilities Property Plant And Equipment Net

Add Fundamental

Total Assets

Total assets refers to the total amount of Armata Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Armata Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Armata Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Armata Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Most accounts from Armata Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Armata Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Armata Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Armata Stock, please use our How to Invest in Armata Pharmaceuticals guide.At this time, Armata Pharmaceuticals' Non Current Liabilities Total is relatively stable compared to the past year. As of 11/26/2024, Other Current Assets is likely to grow to about 2.3 M, while Retained Earnings are likely to drop (324.3 M).

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	38.0M	48.8M	120.4M	126.4M
Total Assets	69.8M	95.8M	98.4M	103.3M

Short Long Term Debt Total Total Assets

Armata Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Net Debt	Non Currrent Assets Other	Net Receivables	Common Stock Total Equity	Short Term Investments	Common Stock
Total Assets		0.9	-0.76	0.88	-0.33	0.97	0.07	0.22	0.63	0.99	0.64	0.96	0.87	0.5	-0.18	0.91	0.97	0.74	0.85	0.32	0.86	0.05	0.82	-0.24	0.13	-0.24
Short Long Term Debt Total	0.9		-0.63	0.78	-0.61	0.94	0.01	0.1	0.42	0.92	0.42	0.9	0.94	0.27	-0.18	0.96	0.94	0.47	0.74	0.17	0.99	0.43	0.88	-0.15	0.02	-0.15
Other Current Liab	-0.76	-0.63		-0.9	0.04	-0.74	-0.04	-0.29	-0.39	-0.73	-0.39	-0.71	-0.51	-0.86	0.08	-0.6	-0.74	-0.67	-0.95	-0.08	-0.61	0.14	-0.6	0.02	0.03	0.02
Total Current Liabilities	0.88	0.78	-0.9		-0.14	0.86	0.08	0.2	0.47	0.87	0.47	0.89	0.65	0.72	-0.14	0.74	0.86	0.67	0.98	0.21	0.75	-0.01	0.66	-0.22	0.12	-0.22
Total Stockholder Equity	-0.33	-0.61	0.04	-0.14		-0.34	0.33	-0.2	-0.29	-0.34	-0.29	-0.25	-0.75	0.36	-0.11	-0.68	-0.33	-0.06	-0.12	-0.16	-0.59	-0.87	-0.35	0.06	0.03	0.06
Property Plant And Equipment Net	0.97	0.94	-0.74	0.86	-0.34		0.16	0.07	0.48	0.97	0.48	0.98	0.85	0.49	-0.27	0.89	1.0	0.63	0.83	0.15	0.93	0.12	0.92	-0.13	0.02	-0.13
Retained Earnings	0.07	0.01	-0.04	0.08	0.33	0.16		-0.44	-0.23	0.08	-0.23	0.19	-0.11	0.37	-0.97	-0.09	0.15	0.05	0.05	-0.37	0.05	-0.28	0.31	0.69	-0.61	0.69
Accounts Payable	0.22	0.1	-0.29	0.2	-0.2	0.07	-0.44		0.3	0.21	0.3	0.03	0.25	0.06	0.42	0.26	0.08	0.25	0.26	0.72	0.08	-0.06	-0.1	-0.36	0.37	-0.36
Cash	0.63	0.42	-0.39	0.47	-0.29	0.48	-0.23	0.3		0.53	1.0	0.51	0.6	0.26	0.17	0.61	0.48	0.89	0.45	0.27	0.3	-0.05	0.26	-0.35	0.33	-0.35
Non Current Assets Total	0.99	0.92	-0.73	0.87	-0.34	0.97	0.08	0.21	0.53		0.54	0.96	0.87	0.45	-0.19	0.91	0.97	0.64	0.83	0.34	0.9	0.1	0.84	-0.25	0.13	-0.25
Cash And Short Term Investments	0.64	0.42	-0.39	0.47	-0.29	0.48	-0.23	0.3	1.0	0.54		0.51	0.61	0.26	0.17	0.61	0.48	0.89	0.45	0.28	0.31	-0.05	0.27	-0.35	0.33	-0.35
Common Stock Shares Outstanding	0.96	0.9	-0.71	0.89	-0.25	0.98	0.19	0.03	0.51	0.96	0.51		0.8	0.51	-0.29	0.85	0.98	0.65	0.84	0.17	0.88	0.05	0.86	-0.2	0.09	-0.2
Non Current Liabilities Total	0.87	0.94	-0.51	0.65	-0.75	0.85	-0.11	0.25	0.6	0.87	0.61	0.8		0.13	-0.08	0.99	0.84	0.54	0.61	0.32	0.9	0.48	0.76	-0.2	0.06	-0.2
Other Current Assets	0.5	0.27	-0.86	0.72	0.36	0.49	0.37	0.06	0.26	0.45	0.26	0.51	0.13		-0.33	0.23	0.49	0.64	0.78	-0.16	0.25	-0.48	0.37	0.24	-0.23	0.24
Other Stockholder Equity	-0.18	-0.18	0.08	-0.14	-0.11	-0.27	-0.97	0.42	0.17	-0.19	0.17	-0.29	-0.08	-0.33		-0.09	-0.26	-0.06	-0.11	0.33	-0.22	0.09	-0.43	-0.7	0.67	-0.7
Total Liab	0.91	0.96	-0.6	0.74	-0.68	0.89	-0.09	0.26	0.61	0.91	0.61	0.85	0.99	0.23	-0.09		0.89	0.59	0.7	0.31	0.92	0.42	0.78	-0.21	0.08	-0.21
Property Plant And Equipment Gross	0.97	0.94	-0.74	0.86	-0.33	1.0	0.15	0.08	0.48	0.97	0.48	0.98	0.84	0.49	-0.26	0.89		0.63	0.83	0.15	0.92	0.1	0.92	-0.14	0.03	-0.14
Total Current Assets	0.74	0.47	-0.67	0.67	-0.06	0.63	0.05	0.25	0.89	0.64	0.89	0.65	0.54	0.64	-0.06	0.59	0.63		0.68	0.1	0.38	-0.28	0.44	-0.14	0.19	-0.14
Short Term Debt	0.85	0.74	-0.95	0.98	-0.12	0.83	0.05	0.26	0.45	0.83	0.45	0.84	0.61	0.78	-0.11	0.7	0.83	0.68		0.18	0.71	-0.05	0.63	-0.17	0.08	-0.17
Intangible Assets	0.32	0.17	-0.08	0.21	-0.16	0.15	-0.37	0.72	0.27	0.34	0.28	0.17	0.32	-0.16	0.33	0.31	0.15	0.1	0.18		0.15	-0.03	-0.09	-0.65	0.5	-0.65
Net Debt	0.86	0.99	-0.61	0.75	-0.59	0.93	0.05	0.08	0.3	0.9	0.31	0.88	0.9	0.25	-0.22	0.92	0.92	0.38	0.71	0.15		0.45	0.89	-0.11	-0.02	-0.11
Non Currrent Assets Other	0.05	0.43	0.14	-0.01	-0.87	0.12	-0.28	-0.06	-0.05	0.1	-0.05	0.05	0.48	-0.48	0.09	0.42	0.1	-0.28	-0.05	-0.03	0.45		0.18	0.01	-0.1	0.01
Net Receivables	0.82	0.88	-0.6	0.66	-0.35	0.92	0.31	-0.1	0.26	0.84	0.27	0.86	0.76	0.37	-0.43	0.78	0.92	0.44	0.63	-0.09	0.89	0.18		0.13	-0.22	0.13
Common Stock Total Equity	-0.24	-0.15	0.02	-0.22	0.06	-0.13	0.69	-0.36	-0.35	-0.25	-0.35	-0.2	-0.2	0.24	-0.7	-0.21	-0.14	-0.14	-0.17	-0.65	-0.11	0.01	0.13		-0.9	1.0
Short Term Investments	0.13	0.02	0.03	0.12	0.03	0.02	-0.61	0.37	0.33	0.13	0.33	0.09	0.06	-0.23	0.67	0.08	0.03	0.19	0.08	0.5	-0.02	-0.1	-0.22	-0.9		-0.9
Common Stock	-0.24	-0.15	0.02	-0.22	0.06	-0.13	0.69	-0.36	-0.35	-0.25	-0.35	-0.2	-0.2	0.24	-0.7	-0.21	-0.14	-0.14	-0.17	-0.65	-0.11	0.01	0.13	1.0	-0.9

Click cells to compare fundamentals

Armata Pharmaceuticals Account Relationship Matchups

Armata Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	25.5M	39.5M	69.8M	95.8M	98.4M	103.3M
Other Current Liab	3.0M	3.5M	658K	(10.8M)	(4.1M)	(3.9M)
Total Current Liabilities	4.9M	6.7M	4.8M	24.9M	16.5M	17.3M
Total Stockholder Equity	14.6M	18.9M	25.4M	36.1M	(32.1M)	(30.5M)
Property Plant And Equipment Net	4.2M	12.8M	38.1M	46.7M	57.3M	60.1M
Retained Earnings	(157.5M)	(179.7M)	(202.9M)	(239.8M)	(308.8M)	(324.3M)
Accounts Payable	547K	956K	1.1M	1.7M	1.6M	1.3M
Cash	6.0M	9.6M	10.3M	14.9M	13.5M	11.2M
Non Current Assets Total	18.8M	28.7M	54.8M	68.8M	79.2M	83.2M
Cash And Short Term Investments	6.0M	9.6M	10.3M	14.9M	13.5M	11.3M
Common Stock Shares Outstanding	7.8M	16.4M	24.1M	34.3M	36.1M	37.9M
Liabilities And Stockholders Equity	25.5M	39.5M	69.8M	95.8M	98.4M	103.3M
Non Current Liabilities Total	6.0M	14.0M	39.6M	34.9M	114.0M	119.7M
Other Current Assets	622K	636K	1.7M	15.9M	2.3M	2.3M
Other Stockholder Equity	172.0M	198.4M	228.0M	275.5M	276.4M	251.6M
Total Liab	10.9M	20.7M	44.4M	59.8M	130.4M	136.9M
Property Plant And Equipment Gross	4.2M	12.8M	48.3M	57.8M	69.1M	72.6M
Total Current Assets	6.7M	10.8M	15.0M	27.0M	19.2M	11.1M
Net Debt	(3.2M)	3.5M	27.7M	34.0M	106.8M	112.2M
Non Currrent Assets Other	836K	(2.1M)	(8.3M)	(9.6M)	8.2M	8.6M
Common Stock Total Equity	99K	187K	271K	361K	324.9K	308.7K
Common Stock	99K	187K	271K	361K	324.9K	308.7K
Capital Surpluse	172.0M	198.4M	228.0M	275.5M	247.9M	245.6M
Property Plant Equipment	4.2M	12.8M	2.2M	3.6M	4.2M	4.4M
Net Tangible Assets	11.1M	15.4M	11.7M	22.3M	25.7M	17.0M
Other Assets	(1K)	23.1M	13.2M	18.6M	21.4M	22.5M
Net Invested Capital	14.6M	19.6M	25.4M	36.1M	50.2M	25.5M
Net Working Capital	1.8M	4.1M	10.2M	2.2M	2.7M	3.5M

Pair Trading with Armata Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Armata Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Armata Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

The ability to find closely correlated positions to Armata Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Armata Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Armata Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Armata Pharmaceuticals to buy it.

The correlation of Armata Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Armata Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Armata Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Armata Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Armata Stock Analysis

When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Armata Historical Balance Sheet

Armata Pharmaceuticals Inventory

(2.56 Million)

About Armata Balance Sheet Analysis

Armata Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

Armata Pharmaceuticals balance sheet Correlations

Armata Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Armata Pharmaceuticals balance sheet Accounts

Pair Trading with Armata Pharmaceuticals

Additional Tools for Armata Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Common Stock	+ 1.0	Common Stock Total Equity
Non Current Assets Total	+ 0.99	Total Assets
Net Debt	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.99	Non Current Liabilities Total

Other Stockholder Equity	- 0.97	Retained Earnings
Short Term Debt	- 0.95	Other Current Liab
Common Stock	- 0.9	Short Term Investments
Short Term Investments	- 0.9	Common Stock Total Equity
Total Current Liabilities	- 0.9	Other Current Liab
Non Currrent Assets Other	- 0.87	Total Stockholder Equity